



Published in final edited form as:

Science. 2022 January 14; 375(6577): 221–225. doi:10.1126/science.abj8432.

Bacterial gasdermins reveal an ancient mechanism of cell death

Alex G. Johnson^{1,2,†}, Tanita Wein^{3,†}, Megan L. Mayer⁴, Brianna Duncan-Lowey^{1,2}, Erez Yirmiya³, Yaara Oppenheimer-Shaanan³, Gil Amitai³, Rotem Sorek^{3,*}, Philip J. Kranzusch^{1,2,5,*}

¹Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA

²Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

³Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel

⁴Harvard Center for Cryo-Electron Microscopy, Harvard Medical School, Boston, MA 02115, USA

⁵Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA 02115, USA

Abstract

Gasdermin proteins form large membrane pores in human cells that release immune cytokines and induce lytic cell death. Gasdermin pore formation is triggered by caspase-mediated cleavage during inflammasome signaling and is critical for defense against pathogens and cancer. We discovered gasdermin homologs encoded in bacteria that defended against phages and executed cell death. Structures of bacterial gasdermins revealed a conserved pore-forming domain that was stabilized in the inactive state with a buried lipid modification. Bacterial gasdermins were activated by dedicated caspase-like proteases that catalyzed site-specific cleavage and the removal of an inhibitory C-terminal peptide. Release of autoinhibition induced the assembly of large and heterogeneous pores that disrupted membrane integrity. Thus, pyroptosis is an ancient form of regulated cell death shared between bacteria and animals.

One-Sentence Summary:

Bacteria encode gasdermins that are activated by dedicated proteases, defend from phage, and induce cell death.

*Corresponding authors. philip_kranzusch@dfci.harvard.edu (PJK); rotem.sorek@weizmann.ac.il (RS).

†These authors contributed equally to this work.

Author contributions: Conceptualization: A.G.J., T.W., G.A., R.S., and P.J.K. Methodology: A.G.J., T.W., M.L.M., B.D.-L., E.Y., Y.O.-S., R.S., and P.J.K. Investigation: A.G.J., T.W., M.L.M., B.D.-L., E.Y., Y.O.-S., R.S., and P.J.K. Visualization: A.G.J., T.W., M.L.M. Funding acquisition: R.S. and P.J.K. Project administration: R.S. and P.J.K. Supervision: R.S. and P.J.K. Writing – original draft: A.G.J., T.W., R.S., and P.J.K. Writing – review & editing: A.G.J., T.W., M.L.M., B.D.-L., E.Y., Y.O.-S., G.A., R.S., and P.J.K.

Competing Interests: R.S. is a scientific cofounder and advisor of BiomX, Pantheon Bioscience, and Ecophage. The remaining authors have no competing financial interests to declare.

Supplementary Materials

Materials and Methods

Figs. S1 to S20

Tables S1 to S6

References (19–47)

Movies S1 to S4

In mammals, gasdermin proteins execute pyroptotic cell death by oligomerizing into membrane pores that release inflammatory cytokines and induce cell lysis. The human genome encodes six gasdermin proteins (GSDMA to GSDME and pejkakin) including the prototypical member GSDMD (1–3). Gasdermin activation requires caspase- or granzyme-mediated cleavage of an inter-domain linker that liberates a lipophilic N-terminal domain (NTD) from a large inhibitory C-terminal domain (CTD) (4–6). Proteolysis enables gasdermin NTD oligomerization and the formation of membrane pores important for innate immunity in mammals and primitive eukaryotes (7–9). Recent structural analyses have explained a mechanism of gasdermin pore formation (5, 6, 10, 11), but the evolutionary origin and biological roles of diverse gasdermin proteins remain unknown (12).

While analyzing bacterial anti-phage defense islands we identified uncharacterized genes with predicted homology to mammalian gasdermins (Table S1). Sequence analysis revealed 50 bacterial gasdermins (bGSDMs) that form a clade distinct from that of eukaryotic homologs (Fig. 1A and fig. S1) (7, 9, 13). We determined crystal structures of bGSDMs from *Bradyrhizobium tropiciagri* and *Vitiosangium sp.*, which revealed that bGSDMs each adopt a shared overall architecture that exhibits notable homology to the mammalian gasdermin NTD (fig. S2B and Table S2), including conservation of a twisted central anti-parallel β sheet and the shared placement of connecting helices and strands throughout the periphery (Fig. 1B–C).

The structures revealed complete absence of the large α -helical CTD required to maintain mammalian gasdermins in an autoinhibited state (Fig. 1). Though lacking the CTD, the bGSDM structures adopted the same conformation as the inactive mammalian gasdermin complex (Fig. 1B–C). In the inactive structure of mammalian GSDMA3, the NTD forms two interfaces with the CTD that mediate autoinhibition, with the primary interface at the α 1 helix and the β 1– β 2 hairpin (Fig. 1C) (5, 11). Cleavage of GSDMA3 results in NTD activation through the lengthening of strands β 3, β 5, β 7, and β 9 and oligomerization of \sim 27 protomers into a membrane-spanning pore (2, 5, 6). Both the *Bradyrhizobium* and *Vitiosangium* bGSDM structures contained strands equivalent to GSDMA3 β 1 to β 2 and β 6 to β 9, but in bGSDMs, a short C-terminal peptide wrapped around the twisted β -sheet core and terminated across strand β 2 to stabilize the inactivated state (Fig. 1B–C).

While building the bGSDM atomic models, we observed a snakelike density protruding from the *Bradyrhizobium* cysteine C3 sidechain. The density occupies a hydrophobic tunnel across the protein that is capped by F25 from the C-terminal peptide. In the 1.5 Å *Bradyrhizobium* bGSDM electron density map, the density could be assigned as a 16-carbon palmitoyl thioester (Fig. 1D and fig. S2C). We confirmed bGSDM palmitoylation with mass spectrometry and found that a cysteine at this position is conserved in gasdermins across most bacteria and some fungi (Fig. 1A and fig. S3A–B). The presence of the palmitoyl in a hydrophobic cavity suggests that bGSDM palmitoylation occurs through autocatalysis (14). Palmitoylation contributes to stability of the inactive state protein (Fig. 1E), and modeling suggests substantial reorganization of residues along the hydrophobic tunnel during bGSDM activation (Fig. 1D and fig. S2C–D) (6).

The majority of bGSMDs (43 of 50) are genomically encoded next to one or more genes with a predicted protease domain (Fig. 2A and fig. S5A–C, Table S1). In most cases, the associated proteases are caspase-like peptidases including peptidase C14 (Pfam database ID PF00656) and CHAT (Pfam ID PF12770) proteases (Fig. 2B and fig. S5A). Fungal gasdermins are also commonly encoded next to protease domain-containing genes (40 of 52) (Table S3 and fig. S5B) and are activated through proteolysis (13). bGSMD-protease systems are found in diverse bacteria and archaea, as well as in metagenomic samples of prokaryotic origin (fig. S5D, Table S4). Analysis of the bGSMD-associated proteases revealed that they are fused to divergent repeat or NACHT domains frequently involved in pathogen recognition and inflammasome function in human innate immunity (Fig. 2B and fig. S5C) (15). bGSMD genes are occasionally encoded near known immune defense systems (Fig. 2A and fig. S7A, Tables S1, S4), so we tested bGSMD systems for a role in anti-phage defense. bGSMD systems evolutionarily distant from the model organism *Escherichia coli* exhibited no discernible phage restriction (fig. S6). However, a four gene operon from *Lysobacter enzymogenes* exhibited robust defense against coliphages T4, T5, and T6 (Fig. 2C–D and fig. S6B–C). Deletion of the bGSMD gene from the *Lysobacter* operon abolished protection (Fig. 2C–D and fig. S6C). Thus, the bGSMD is essential for defense.

Expression of some of the bGSMD-protease systems in *E. coli* induced potent cellular toxicity in the absence of phage infection (Fig. 2E–F, fig. S7B–C, and Table S5). Particularly strong toxicity was observed for a *Runella* system, which required bGSMD palmitoylation (Fig. 2E and fig. S7B–C). Time-lapse microscopy in the presence of propidium iodide (PI) showed that cells expressing the *Runella* system ceased dividing and lost membrane integrity, which suggests that bGSMD activation induces membrane disruption (Fig. 2E–F and fig. S7D, Movies S1–S2). Mutation of the predicted *Runella* caspase-like protease active site residues H796 and C840 ablated all cellular toxicity (Fig. 3A). The *Runella* bGSMD and protease only induced cellular toxicity when expressed together, which suggests that the protease targets bGSMD during system activation (Fig. 3A and fig. S8A). In fact, a mutation that disrupted the active site of the second trypsin-like protease in the *Lysobacter* bGSMD system abolished anti-phage defense (fig. S8B).

We focused on the *Runella* system and reconstituted cleavage with purified components (Fig. 3B and fig. S8A–F). Co-incubation with the protease resulted in specific bGSMD cleavage and formation of a lower molecular weight *Runella* bGSMD species (fig. S8A). Cleavage requires the protease catalytic residues but not bGSMD palmitoylation (Fig. 3B and fig. S8D–E). Using mass spectrometry, we determined that the *Runella* bGSMD cleavage site occurs after the P1 residue L247 (fig. S9A–B). A 2.9 Å structure of the *Runella* bGSMD (Table S2) revealed that cleavage occurs in a loop that immediately precedes the C-terminal peptide (Fig. 3C–D). Packing in the *Runella* bGSMD crystal lattice additionally indicates an ability of the peptide to dissociate from the bGSMD face which supports release after cleavage (fig. S10A).

Analysis of the high-resolution *Bradyrhizobium* bGSMD structure explains how the C-terminal peptide restrains the bGSMD core (Fig. 3E). *Bradyrhizobium* bGSMD F245 and F247 lay along the surface formed between the mammalian $\beta 9$ strand and the $\alpha 1$

helix equivalent positions and are further supported with contacts between N21 and the peptide backbone. A *Bradyrhizobium*-specific β -strand from N21 to L24 extends off the β 9 strand equivalent and is supported by a short parallel β strand from F253 to D255. *Bradyrhizobium* bGSDM F253 latches over the palmitoyl modification, with similar hydrophobic contacts also observed in the *Runella* and *Vitiosangium* structures (fig. S10A–B). The *Bradyrhizobium* bGSDM C-terminal peptide terminates below the strand equivalent to β 2 and is supported by hydrogen bonds from R27 to the L256 backbone and N29 to E258. Truncation of the C-terminal peptide in the *Runella*, *Bradyrhizobium*, or *Vitiosangium* bGSDM constructs led to arrested cell growth which confirms that the C-terminal peptide is required to maintain the bGSDM autoinhibition (fig. S11A–B).

We next used mutagenesis of the *Runella* bGSDM system to define the specificity of proteolytic cleavage and bGSDM activation. In vitro, the L247 P1 position was essential for cleavage, and proteolysis was inhibited by mutations that disrupt the P1' glycine and the P4, P3, P2 and P3' residues (fig. S11C–D). Likewise, mutations that disrupt the P1 and P1' positions eliminated toxicity in vivo (fig. S11E–F). The *Runella* protease was not capable of activating divergent bGSDMs engineered to contain the *Runella* cleavage loop, which suggests that additional contacts specify bGSDM recognition (fig. S11G–H). Thus, like their mammalian homologs, bGSDMs are cell death effectors activated by proteolytic cleavage.

To determine whether activated bGSDMs associate with bacterial membranes, we fused green fluorescent protein (GFP) to the N-terminus of the *Runella* bGSDM and visualized expression in *E. coli*. Upon co-expression with the *Runella* protease, GFP-bGSDM coalesced into membrane-associated puncta and induced cellular toxicity (Fig. 4A and fig. S12A–C). Transmission electron microscopy analysis of *E. coli* expressing the active *Runella* bGSDM system revealed clear disruption of membrane integrity (fig. S13A–C). In vitro reconstituted *Runella* bGSDM activity demonstrated that cleaved *Runella* bGSDMs permeabilized liposomes and caused rapid release of the internal contents (Fig. 4B and fig. S14A–B). Protease active-site or bGSDM cleavage-site mutations disrupted all liposome permeabilization, which confirms that proteolysis is essential for bGSDM activation (Fig. 4B and fig. S14B). Blocking bGSDM palmitoylation with mutation of residue C3 reduced but did not abolish liposome leakage or membrane-associated puncta formation in cells (Fig. 4B and fig. S12A). Likewise, a C7A mutation to the putative *Lysobacter* bGSDM palmitoylation site was not sufficient to abolish anti-phage defense (fig. S8B), which suggests that lipid-modification supports but is not required for membrane permeabilization.

To compare the bGSDM pore with its mammalian counterparts, we used electron microscopy to visualize *Runella* bGSDM cleavage reactions and liposomes (Fig. 4C and fig. S15A–C). bGSDM pores were observed within liposomes and as fragmented mesh-like arrays. Cryo-electron microscopy (cryo-EM) and two-dimensional (2D) classification analysis of detergent-solubilized complexes revealed that *Runella* bGSDM forms a ring-like pore that exhibits a width of ~ 50 Å and an inner diameter ranging from 200 to 300 Å (fig. S17A–D). *Runella* bGSDM pores within liposomes measured ~ 240 to 330 Å, modestly larger than the 135 to 215 Å mammalian gasdermin pores (fig. S17A–D) (6, 10, 16). We also reconstituted cleavage of a bGSDM from a metagenomic *Bacteroidetes* scaffold and observed smaller 130 to 190 Å pores within liposomes, which suggests heterogeneity in

the architecture of diverse bGSDM pores (fig. S18A–D and fig. S19A–C). Cryo-electron tomography (cryo-ET) tilt series reconstructions of the pore-liposome assemblies confirmed that bGSDM pores span the liposomal surface to disrupt membrane integrity (Fig. 4D, fig. S20, and Movie S3–S4).

Our results support a model for gasdermin pore formation and effector function that has notable parallels between bacteria and mammals (Fig. 4E). bGSDM systems can exert antiphage defense, and the fusion of bGSDM-associated proteases with NACHT and repeat domains suggests that similar to inflammasome sensors in mammals, foreign pathogen recognition may control the initiation of gasdermin cleavage (Fig. 2B–D) (15, 17). In both mammalian gasdermin and bGSDM systems, proteolytic cleavage after the lipophilic NTD releases gasdermin inhibition. The notably short C-terminal peptide responsible for bGSDM inhibition suggests the possibility that short-form eukaryotic gasdermins including pejkakin may undergo activation through a similar mechanism. Furthermore, widespread palmitoylation of bGSDMs indicates that cysteine modifications are a conserved mechanism for regulating gasdermin pores (18). The size distribution of pores from *Runella* and *Bacteroidetes* species might suggest that bGSDM pores, like those in mammals, could be customized for the secretion of certain molecules (10). Defining the cues that activate bGSDM systems will provide insight into their roles in prokaryotic biology and the origins of pyroptotic cell death.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

The authors thank members of the Kranzusch and Sorek laboratories for helpful discussions. Mass spectrometry was performed at the Biopolymers and Proteomics Core Facility at the Koch Institute of MIT, the Taplin Mass Spectrometry Facility at Harvard Medical School, and the Weizmann De Botton Protein Profiling Institute. We thank W. Shih's laboratory for training and use of the JEOL-1400 electron microscope, the Harvard Center for Cryo-Electron Microscopy (HC2EM), the HMS Electron Microscopy Facility, M. Eck for sharing computational resources, and the SBGrid consortium for computational support. We thank J. Leitz and A. Brunger for sharing scripts for cryo-ET reconstruction.

Funding:

This study was supported by the Pew Biomedical Scholars Program (P.J.K.), the Burroughs Wellcome Fund PATH award (P.J.K.)

Mathers Foundation (P.J.K.), the Parker Institute for Cancer Immunotherapy (P.J.K.), the European Research Council grant ERC-CoG 681203 (R.S.), the Israel Science Foundation grant ISF 296/21 (R.S.), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine (R.S.), the Minerva Foundation and Federal German Ministry for Education and Research (R.S.), the Knell Family Center for Microbiology (R.S.), the Yotam project and the Weizmann Institute Sustainability And Energy Research Initiative (R.S.), the Dr. Barry Sherman Institute for Medicinal Chemistry (R.S.), the National Institute of Health Cancer Immunology training grant T32CA207021 (A.G.J.), a Life Science Research Foundation postdoctoral fellowship of the Open Philanthropy Project (A.G.J.), a Minerva Foundation postdoctoral fellowship (T.W.), and a Herchel Smith Graduate Research Fellowship (B.D.-L.).

Data and Materials Availability:

Atomic coordinates and structure factors for the reported crystal structures have been deposited with the Protein Data Bank under accession numbers 7N50 (*Bradyrhizobium* bGSDM), 7N51 (*Vitiosangium* bGSDM), and 7N52 (*Runella* bGSDM). Correspondence and requests for other materials should be addressed to PJK or RS.

References and Notes

- Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, Liu PS, Lill JR, Li H, Wu J, Kummerfeld S, Zhang J, Lee WP, Snipas SJ, Salvesen GS, Morris LX, Fitzgerald L, Zhang Y, Bertram EM, Goodnow CC, Dixit VM, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 526, 666–671 (2015). [PubMed: 26375259]
- Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature*. 526, 660–665 (2015). [PubMed: 26375003]
- He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang ZH, Zhong CQ, Han J, Gasdermin D is an executor of pyroptosis and required for interleukin-1 β secretion. *Cell Res*. 25, 1285–1298 (2015). [PubMed: 26611636]
- Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J, Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. *Nature*. 535, 153–158 (2016). [PubMed: 27383986]
- Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang DC, Shao F, Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature*. 535, 111–116 (2016). [PubMed: 27281216]
- Ruan J, Xia S, Liu X, Lieberman J, Wu H, Cryo-EM structure of the gasdermin A3 membrane pore. *Nature*. 557, 62–67 (2018). [PubMed: 29695864]
- Jiang S, Zhou Z, Sun Y, Zhang T, Sun L, Coral gasdermin triggers pyroptosis. *Sci. Immunol.* 5 (2020), doi:eabd2591.
- Lieberman J, Wu H, Kagan JC, Gasdermin D activity in inflammation and host defense. *Sci. Immunol.* 4, eaav1447 (2019). [PubMed: 31492708]
- Daskalov A, Mitchell PS, Sandstrom A, Vance RE, Glass NL, Molecular characterization of a fungal gasdermin-like protein. *Proc. Natl. Acad. Sci. U. S. A.* 117, 18600–18607 (2020). [PubMed: 32703806]
- Xia S, Zhang Z, Magupalli VG, Pablo JL, Dong Y, Vora SM, Wang L, Fu TM, Jacobson MP, Greka A, Lieberman J, Ruan J, Wu H, Gasdermin D pore structure reveals preferential release of mature interleukin-1. *Nature*. 593, 607–611 (2021). [PubMed: 33883744]
- Liu Z, Wang C, Yang J, Zhou B, Yang R, Ramachandran R, Abbott DW, Xiao TS, Crystal Structures of the Full-Length Murine and Human Gasdermin D Reveal Mechanisms of Autoinhibition, Lipid Binding, and Oligomerization. *Immunity*. 51, 43–49.e4 (2019). [PubMed: 31097341]
- Broz P, Pelegrín P, Shao F, The gasdermins, a protein family executing cell death and inflammation. *Nat. Rev. Immunol.* 20, 143–157 (2020). [PubMed: 31690840]
- Clavé C, Dyrka W, Granger-Farbos A, Pinson B, Saupe SJ, Daskalov A, Fungal gasdermin-like proteins are controlled by proteolytic cleavage. UPDATE IF POSSIBLE bioRxiv (2021), doi:10.1101/2021.06.03.446900.
- Kümmel D, Heinemann U, Veit M, Unique self-palmitoylation activity of the transport protein particle component Bet3: A mechanism required for protein stability. *Proc. Natl. Acad. Sci. U. S. A.* 103, 12701–12706 (2006). [PubMed: 16908848]
- Shi M, Zhang P, Vora SM, Wu H, Higher-order assemblies in innate immune and inflammatory signaling: A general principle in cell biology. *Curr. Opin. Cell Biol.* 63, 194–203 (2020). [PubMed: 32272435]

16. Hansen JM, de Jong MF, Wu Q, Zhang L, Heisler DB, Alto LT, Alto NM, Pathogenic ubiquitination of GSDMB inhibits NK cell bactericidal functions. *Cell*, 1–14 (2021). [PubMed: 33417857]
17. Kaur G, Burroughs AM, Iyer LM, Aravind L, Highly-regulated, diversifying NTP-dependent biological conflict systems with implications for the emergence of multicellularity. *Elife*. 9, 1–45 (2020).
18. Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, Wilson R, Jiang Z, Khalighinejad F, Muneeruddin K, Shaffer SA, Dutta R, Ionete C, Pesiridis S, Yang S, Thompson PR, Fitzgerald KA, Succination inactivates gasdermin D and blocks pyroptosis. *Science*. 369, 1633–1637 (2020). [PubMed: 32820063]
19. Chen I-MA, Chu K, Palaniappan K, Pillay M, Ratner A, Huang J, Huntemann M, Varghese N, White JR, Seshadri R, Smirnova T, Kirton E, Jungbluth SP, Woyke T, Eloie-Fadrosh EA, Ivanova NN, Kyrpidis NC, IMG/M v.5.0: an integrated data management and comparative analysis system for microbial genomes and microbiomes. *Nucleic Acids Res*. 47, D666–D677 (2019). [PubMed: 30289528]
20. Millman A, Melamed S, Amitai G, Sorek R, Diversity and classification of cyclic-oligonucleotide-based anti-phage signalling systems. *Nat. Microbiol*. 5, 1608–1615 (2020). [PubMed: 32839535]
21. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol. Syst. Biol*. 7 (2011), doi:10.1038/msb.2011.75.
22. Söding J, Protein homology detection by HMM-HMM comparison. *Bioinformatics*. 21, 951–60 (2005). [PubMed: 15531603]
23. Zimmermann L, Stephens A, Nam S-Z, Rau D, Kübler J, Lozajic M, Gabler F, Söding J, Lupas AN, Alva V, A Completely Reimplemented MPI Bioinformatics Toolkit with a New HHpred Server at its Core. *J. Mol. Biol*. 430, 2237–2243 (2018). [PubMed: 29258817]
24. Pei J, V Grishin N, PROMALS3D: multiple protein sequence alignment enhanced with evolutionary and three-dimensional structural information. *Methods Mol. Biol*. 1079, 263–71 (2014). [PubMed: 24170408]
25. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG, Clustal W and Clustal X version 2.0. *Bioinformatics*. 23, 2947–2948 (2007). [PubMed: 17846036]
26. Letunic I, Bork P, Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res*. 47, W256–W259 (2019). [PubMed: 30931475]
27. Katoh K, Rozewicki J, Yamada KD, MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief. Bioinform*. 20, 1160–1166 (2019). [PubMed: 28968734]
28. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R, IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol. Biol. Evol*. 37, 1530–1534 (2020). [PubMed: 32011700]
29. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S, Feolo M, Geer LY, Helmsberg W, Kapustin Y, Khovayko O, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Ostell J, Pruitt KD, Schuler GD, Shumway M, Sequeira E, Sherry ST, Sirotkin K, Souvorov A, Starchenko G, Tatusov RL, Tatusova TA, Wagner L, Yaschenko E, Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res*. 36, D13–D21 (2007). [PubMed: 18045790]
30. Steinegger M, Söding J, MMseqs2 enables sensitive protein sequence searching for the analysis of massive data sets. *Nat. Biotechnol*. 35, 1026–1028 (2017). [PubMed: 29035372]
31. Kabsch W, Integration, scaling, space-group assignment and post-refinement. *Acta Crystallogr. Sect. D Biol. Crystallogr*. 66, 133–144 (2010). [PubMed: 20124693]
32. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. Sect. D Biol. Crystallogr*. 66, 213–221 (2010). [PubMed: 20124702]

33. Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, Moriarty NW, Oeffner RD, Poon BK, Prisant MG, Read RJ, Richardson JS, Richardson DC, Sammito MD, Sobolev OV, Stockwell DH, Terwilliger TC, Urzhumtsev AG, Videau LL, Williams CJ, Adams PD, Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. *Acta Crystallogr. Sect. D Struct. Biol.* 75, 861–877 (2019). [PubMed: 31588918]
34. Emsley P, Cowtan K, Coot: Model-building tools for molecular graphics. *Acta Crystallogr. Sect. D Biol. Crystallogr.* 60, 2126–2132 (2004). [PubMed: 15572765]
35. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC, MolProbity: All-atom structure validation for macromolecular crystallography. *Acta Crystallogr. Sect. D Biol. Crystallogr.* 66, 12–21 (2010). [PubMed: 20057044]
36. Karplus PA, Diederichs K, Linking crystallographic model and data quality. *Science.* 336, 1030–1033 (2012). [PubMed: 22628654]
37. Weiss MS, Global indicators of X-ray data quality. *J. Appl. Crystallogr.* 34, 130–135 (2001).
38. Käll L, Storey JD, Noble WS, Non-parametric estimation of posterior error probabilities associated with peptides identified by tandem mass spectrometry. *Bioinformatics.* 24, 42–48 (2008). [PubMed: 18057021]
39. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, A statistical model for identifying proteins by tandem mass spectrometry. *Anal. Chem.* 75, 4646–4658 (2003). [PubMed: 14632076]
40. Mazzocco A, Waddell TE, Lingohr E, Johnson RP, Enumeration of bacteriophages using the small drop plaque assay system. *Methods Mol. Biol.* 501, 81–5 (2009). [PubMed: 19066813]
41. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M, Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment. *J. Proteome Res.* 10, 1794–1805 (2011). [PubMed: 21254760]
42. Schorb M, Haberbosch I, Hagen WJH, Schwab Y, Mastronarde DN, Software tools for automated transmission electron microscopy. *Nat. Methods.* 16, 471–477 (2019). [PubMed: 31086343]
43. Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA, MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods.* 14, 331–332 (2017). [PubMed: 28250466]
44. Rohou A, Grigorieff N, CTFIND4: Fast and accurate defocus estimation from electron micrographs. *J. Struct. Biol.* 192, 216–221 (2015). [PubMed: 26278980]
45. Scheres SHW, RELION: Implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol.* 180, 519–530 (2012). [PubMed: 23000701]
46. Wagner T, Merino F, Stabrin M, Moriya T, Antoni C, Apelbaum A, Hagel P, Sitsel O, Raisch T, Prumbaum D, Quentin D, Roderer D, Tacke S, Siebolds B, Schubert E, Shaikh TR, Lill P, Gatsogiannis C, Raunser S, SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. *Commun. Biol.* 2, 1–13 (2019). [PubMed: 30740537]
47. Mastronarde DN, Dual-axis tomography: an approach with alignment methods that preserve resolution. *J. Struct. Biol.* 120, 343–52 (1997). [PubMed: 9441937]




Fig. 1. Structures of bGSDMs reveal homology with mammalian cell death effectors.

(A) Gasdermin phylogenetic tree. The sizes of the gasdermin NTDs and CTDs are depicted. Vertebrate gasdermins are labeled with single letters indicating human gasdermins GSDMA to GSDME (“A” to “E”), and “P” depicts pejkakin. The black teardrop indicates a conserved N-terminal cysteine(N-termin cys). A representative set of 20 fungal gasdermins are included in the tree. aa, amino acid. (B) Crystal structures of bGSDMs from species of the genera *Bradyrhizobium* and *Vitosangium*. bGSDM structures reveal homology to the NTD of mammalian gasdermins in an inactive conformation including mouse GSDMA3 (Protein Data Bank ID 5B5R). (C) Gasdermin topology diagrams indicate a conserved central core of the bacterial and mammalian NTD. bGSDMs notably lack the CTD required for autoinhibition of mammalian gasdermins and instead encode a short C-terminal peptide. (D) Simulated annealing F_0-F_C omit map (contoured at 3.0σ) from the *Bradyrhizobium* bGSDM fit with a palmitoyl modification at C3. Omit map is shown as green mesh and select residues forming a hydrophobic pocket around the palmitoyl group are indicated. (E) Melting temperatures (T_m) of bGSDMs with and without N-terminal cysteines, as determined with thermofluor assays. Data are the mean and standard deviation of three technical replicates and are representative of three independent experiments. WT, wild-type.

Single-letter abbreviation for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 2. bGSDMs are associated with proteases, defend from phages, and execute cell death. (A) Representative instances of bGSDMs and associated proteases, in their genomic neighborhoods. Genes known to be involved in anti-phage defense are shown in yellow. TA, toxin-antitoxin; Abi, abortive infection; ATPase, adenosine triphosphatase. (B) Types of proteases found adjacent to bGSDMs (n = 59). Some bGSDMs appear with more than one adjacent protease. Caspase-like proteases include peptidase C14 (n = 15) and CHAT (n = 23). Cases in which the protease gene also encodes an additional domain are indicated. TPR, tetratricopeptide repeat; LRR, leucine-rich repeat. (C) A bGSDM-containing operon protects against phages. The efficiency of plating of phages on *E. coli* MG1655 cells expressing the *Lysobacter* bGSDM WT or mutated operon is shown. Data represent plaque-forming units (PFU) per milliliter and are the averages of three independent replicates, with individual data points overlaid. GFP represents a control strain. Statistical significance was determined by a one-way analysis of variance (ANOVA) and Tukey multiple comparison test. Not significant (n.s.) 0.05, ***P* = 0.001 to 0.01. (D) Growth of liquid cultures of *E. coli* expressing the WT and mutated *Lysobacter* bGSDM operons. Cells were infected with phage T6. For each experiment, data represent one out of three biological replicates (replicates are shown in Fig. S6). OD₆₀₀, optical density at 600 nm. (E) The *Runella* bGSDM operon causes cell death. *E. coli* DH5α cells expressing the *Runella* protease and WT or C3A mutated bGSDM were examined by time lapse microscopy. Overlay images from PI (red) and phase contrast of cells captured at the start of the experiment and after 120 min of incubation are shown. Scale bar, 2 μm. (F) bGSDM operons are toxic. Cells encoding protease and WT or mutated

bGDSM were plated in 10-fold serial dilution on LB-agar in conditions that repress operon expression (1% glucose) or induce expression (0.2% arabinose).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 3. bGSDMs are activated by proteolytic cleavage.

(A) Toxicity of *Runella* bGSDM in vivo requires the associated protease. Bacteria expressing WT and mutated versions of the *Runella* bGSDM–protease operon were grown on LB-agar in conditions that repress or induce expression. Data represent colony-forming units (CFU) per milliliter, and bar graphs represent an average of three independent replicates, with individual data points overlaid. Asterisks indicate statistically significant differences compared with the respective noninduced control using two-sided t-test. n.s. 0.05; *** $P = 0.0001$ –0.001; **** $P < 0.0001$. (B) *Runella* bGSDM cleavage by its associated protease is dependent on catalytic histidine and residues in vitro. 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) were run after cleavage at room temperature for 18 h and visualized by Coomassie staining. (C) The *Runella* bGSDM crystal structure and protease cleavage site. The *Runella* bGSDM structure is shown in lavender with the last 21 amino acids highlighted as gray spheres. (D) Close-up view of the *Runella* bGSDM cleavage site wherein cleavage occurs after the P1 L247 residue. (E) Structural overview of the *Bradyrhizobium* CTD and autoinhibitory interactions. The bGSDM is colored purple except for its last 16 residues, which are colored yellow. Insets show interactions of F245 and F247 adjacent to D21 of the N-terminal β sheet (top) and F253 and the palmitoyl modification at C3 (bottom). The $2F_o - F_c$ (contoured at 1.5σ) map is shown as gray mesh fit to the last 16 residues.




Fig. 4. Cleaved bGSMDs form membrane pores to elicit cell death.

(A) GFP was fused to the N-terminus of the *Runella* bGSMD. Cells expressing GFP-bGSMD alone (top) or with the caspase-like protease (bottom) are shown. GFP is colored green. Membrane dye (FM4-64) is in magenta. Scale bar, 1 μ m. (B) Cleaved *Runella* gasdermin permeabilizes liposome membranes. Relative fluorescence units (RFU) were measured continuously from cleavage reactions of dioleoylphosphatidylcholine (DOPC) liposomes loaded with TbCl₃ with an external solution containing 20 μ M dipicolonic acid (DPA). The top plot represents an example of time-course liposome leakage, whereas the bottom bar chart shows values for each condition at 60 min. Error bars represent the SEM of three technical replicates and statistical significance was determined by one-way ANOVA and Tukey multiple comparison test. n.s. 0.05; ** P = 0.001–0.01; **** P < 0.0001. (C) Negative stain electron microscopy of *Runella* gasdermin pores in DOPC liposomes (left) and in mesh-like arrays (right). Scale bars, 50 nm. (D) Slices from representative tomogram (1 of 10) of *Runella* gasdermin pores in DOPC liposomes, at three different depths (Z). Yellow arrowheads indicate pores inserted within the liposome membrane. Scale bars, 50 nm. (E) Model of pyroptosis for bGSMDs and mammalian gasdermins.